These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27558979)

  • 1. Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study.
    Mundal L; Veierød MB; Halvorsen T; Holven KB; Ose L; Iversen PO; Tell GS; Leren TP; Retterstøl K
    Eur J Prev Cardiol; 2016 Dec; 23(18):1962-1969. PubMed ID: 27558979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013.
    Mundal L; Igland J; Ose L; Holven KB; Veierød MB; Leren TP; Retterstøl K
    Eur J Prev Cardiol; 2017 Jan; 24(2):137-144. PubMed ID: 27794106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia.
    Mundal LJ; Igland J; Veierød MB; Holven KB; Ose L; Selmer RM; Wisloff T; Kristiansen IS; Tell GS; Leren TP; Retterstøl K
    Heart; 2018 Oct; 104(19):1600-1607. PubMed ID: 29622598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study.
    de Isla LP; Vallejo-Vaz AJ; Watts GF; Muñiz-Grijalvo O; Alonso R; Diaz-Diaz JL; Arroyo-Olivares R; Aguado R; Argueso R; Mauri M; Romero MJ; Álvarez-Baños P; Mañas D; Cepeda JM; Gonzalez-Bustos P; Casañas M; Michan A; Muñoz-Torrero JFS; Faedo C; Barba MA; Dieguez M; de Andrés R; Hernandez AM; Gonzalez-Estrada A; Padró T; Fuentes F; Badimon L; Mata P;
    Lancet Diabetes Endocrinol; 2024 Sep; 12(9):643-652. PubMed ID: 39098315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excess Aortic Pathology Risk in Patients with Genetically Verified Familial Hypercholesterolaemia: A Prospective Norwegian Registry Study.
    Mundal LJ; Igland J; Leren TP; Retterstøl K
    Eur J Vasc Endovasc Surg; 2021 Apr; 61(4):712-713. PubMed ID: 33485759
    [No Abstract]   [Full Text] [Related]  

  • 6. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010.
    Mundal L; Sarancic M; Ose L; Iversen PO; Borgan JK; Veierød MB; Leren TP; Retterstøl K
    J Am Heart Assoc; 2014 Dec; 3(6):e001236. PubMed ID: 25468658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial hypercholesterolaemia: the Cape Town experience.
    Firth JC; Marais AD
    S Afr Med J; 2008 Feb; 98(2):99-104. PubMed ID: 18350202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study.
    Iyen B; Qureshi N; Kai J; Akyea RK; Leonardi-Bee J; Roderick P; Humphries SE; Weng S
    Atherosclerosis; 2019 Aug; 287():8-15. PubMed ID: 31181417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study.
    Toleikyte I; Retterstøl K; Leren TP; Iversen PO
    Circulation; 2011 Oct; 124(15):1606-14. PubMed ID: 21911783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades.
    Elis A; Zhou R; Stein EA
    Cardiol Young; 2014 Jun; 24(3):437-41. PubMed ID: 23659280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study).
    Pérez de Isla L; Alonso R; Mata N; Fernández-Pérez C; Muñiz O; Díaz-Díaz JL; Saltijeral A; Fuentes-Jiménez F; de Andrés R; Zambón D; Piedecausa M; Cepeda JM; Mauri M; Galiana J; Brea Á; Sanchez Muñoz-Torrero JF; Padró T; Argueso R; Miramontes-González JP; Badimón L; Santos RD; Watts GF; Mata P
    Circulation; 2017 May; 135(22):2133-2144. PubMed ID: 28275165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRP1 gene polymorphisms are associated with premature risk of cardiovascular disease in patients with familial hypercholesterolemia.
    Aledo R; Alonso R; Mata P; Llorente-Cortés V; Padró T; Badimon L
    Rev Esp Cardiol (Engl Ed); 2012 Sep; 65(9):807-12. PubMed ID: 22819221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.
    Santos RD; Gidding SS; Hegele RA; Cuchel MA; Barter PJ; Watts GF; Baum SJ; Catapano AL; Chapman MJ; Defesche JC; Folco E; Freiberger T; Genest J; Hovingh GK; Harada-Shiba M; Humphries SE; Jackson AS; Mata P; Moriarty PM; Raal FJ; Al-Rasadi K; Ray KK; Reiner Z; Sijbrands EJ; Yamashita S;
    Lancet Diabetes Endocrinol; 2016 Oct; 4(10):850-61. PubMed ID: 27246162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia.
    Real JT; Chaves FJ; Martínez-Usó I; García-García AB; Ascaso JF; Carmena R
    Eur Heart J; 2001 Mar; 22(6):465-71. PubMed ID: 11237541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
    Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors.
    Alonso R; Mata N; Castillo S; Fuentes F; Saenz P; Muñiz O; Galiana J; Figueras R; Diaz JL; Gomez-Enterría P; Mauri M; Piedecausa M; Irigoyen L; Aguado R; Mata P;
    Atherosclerosis; 2008 Oct; 200(2):315-21. PubMed ID: 18243212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
    Iyen B; Qureshi N; Weng S; Roderick P; Kai J; Capps N; Durrington PN; McDowell IF; Soran H; Neil A; Humphries SE
    Atherosclerosis; 2020 Dec; 315():131-137. PubMed ID: 33187671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients.
    Jansen AC; van Aalst-Cohen ES; Tanck MW; Trip MD; Lansberg PJ; Liem AH; van Lennep HW; Sijbrands EJ; Kastelein JJ
    J Intern Med; 2004 Dec; 256(6):482-90. PubMed ID: 15554949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia.
    Bhatnagar D; Morgan J; Siddiq S; Mackness MI; Miller JP; Durrington PN
    BMJ; 2000 Dec; 321(7275):1497-500. PubMed ID: 11118175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.